What is C2N Diagnostics?
C2N Diagnostics operates as a specialized diagnostics firm dedicated to the mission of Clarity Through Innovation. The company provides high-value laboratory services and diagnostic products specifically engineered to improve outcomes in brain health. By focusing on biomarker-based diagnostics, C2N enables healthcare providers to optimize clinical decision-making, monitor treatment progress, and streamline the development of novel therapies for neurodegeneration. Their platform serves as a critical infrastructure for researchers and clinicians alike, facilitating a deeper understanding of disease mechanisms and supporting large-scale epidemiological studies that are essential for advancing global neurological care.
How much funding has C2N Diagnostics raised?
C2N Diagnostics has raised a total of $40M across 3 funding rounds:
Grant
$15M
Unspecified
$15M
Other Financing Round
$10M
Grant (2023): $15M with participation from GHR Foundation
Unspecified (2024): $15M led by us.eisai.com
Other Financing Round (2025): $10M supported by Samsung C&T
Key Investors in C2N Diagnostics
GHR Foundation
GHR Foundation is a philanthropic organization dedicated to supporting transformational initiatives, with a specific focus on Alzheimer's prevention and the fostering of early detection technologies.
us.eisai.com
Eisai is a global pharmaceutical company driven by a human health care philosophy, focusing on innovation in neurology and oncology to meet the evolving needs of patients.
Samsung C&T
Samsung C&T is a diversified global conglomerate with extensive interests in engineering, trade, and service industries, providing strategic support for large-scale industrial and technological growth.
What's next for C2N Diagnostics?
With the successful closure of this major strategic investment, C2N Diagnostics is well-positioned to scale its laboratory operations and expand the reach of its biomarker services. The company is expected to prioritize the integration of its diagnostic tools into broader clinical trial frameworks, thereby accelerating the validation of new treatments for neurodegenerative conditions. Furthermore, the influx of capital will likely support the refinement of their diagnostic pipeline, enabling the firm to address unmet needs in early detection and patient monitoring. As the company matures, its focus will remain on bridging the gap between laboratory innovation and practical clinical application, ensuring that its diagnostic solutions continue to set the standard for excellence in the field of brain health.
See full C2N Diagnostics company page
